They used these models to perform a large-scale 1×1×1 (1 mouse representing 1 patient tumor in1 treatment group) trial to retrospectively verify the results of clinical trials testing BRAF inhibitors and the BRAF/MEK inhibitor combination in BRAF mutant melanoma [132]. Here, BRAF is linked to neoplasm.